Michael J. Silverstein, BA, is a Doctoral Candidate, Department of Psychology, Drexel University; and a per diem Research Data Associate, Department of Psychiatry, New York University School of Medicine. Terry L. Leon, MS, RN, is a Senior Clinical Research Coordinator, Department of Psychiatry, New York University School of Medicine. Beth Krone, PhD, is an Assistant Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai. Stephen V. Faraone, PhD, is a Professor and Vice Chair for Research, Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University. Jeffrey H. Newcorn, MD, is a Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai. Lenard A. Adler, MD, is a Vice-Chair, CME, Professor, Department of Psychiatry; a Professor, Department of Child and Adolescent Psychiatry; and the Director, Adult ADHD Program, New York University School of Medicine.
Address correspondence to Lenard A. Adler, MD, Department of Psychiatry and Child and Adolescent Psychiatry, New York University School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016; email:
Grant: Funding for this trial was provided by an investigator-initiated (L.A.A. and J.H.N.) grant (NCT02635035) from Shire Pharmaceuticals awarded to New York University; Mt. Sinai (B.K. and J.H.N) was funded through a subcontract from New York University.
Disclosure: Stephen V. Faraone reports that he receives income, potential income, travel expenses, continuing education support and/or research support from Ironshore, Shire, Akili, Enzymotec, Sunovion, and Genomind; previously received support from Neuorvance, Alcobra, Rhodes, Cogcubed, KemPharm, Neurolifesciences, Lundbeck/Takeda, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly; receives royalites from Guilford Press and Oxford University Press; and receives grant support from the European Union's Seventh Framework Programme for Research, the European Union's Horizon 2020 Research and Innovation Programme, the National Institute of Mental Health. Jeffrey H. Newcorn reports he is/has been an advisor and/or consultant for Adlon Therapeutics, Akili Interactive, Alcobra, Arbor, Cingulate Therapeutics, Enzymotec, KemPharm, Lundbeck/Takeda, Medice, NLS, Rhodes, Shire, and Supernus; a Data and Safety Monitoring Board member for Pfizer and Sunovion; received research funds from Enzymotec, Otsuka, Shire, and Supernus; received speaker fees from Shire for disease-state presentations; and served as a consultant for the US National Football League. Lenard A. Adler is a consultant for Shire, Otsuka, Enzymotec, Sunovion, Bracket, Alcobra, Major League Baseball, the National Football League, Rhodes, and the State University of New York; receives grants from Sunovion, Lunbeck, Enzymotec; and royalty payments from New York Univesity School of Medicine for scales and training material for adult attention-deficit/hyperactivity disorders. The remaining authors have no relevant financial relationships to disclose.
The authors thank Amanda Kirschenbaum (Mount Sinai), Daniela Barrera (NYU), Sarah Laury (NYU), and Jonathan Yuh (NYU) for assistance with data collection and entry; Glenn Hirsch, MD (NYU) for his help in the conduct of the trial; and Russell Barkley, PhD (Virginia Commenwealth University School of Medicine) for his assistance in interpretation of the findings.